Clinical Trials
16 trialsNCT04165772 2026-05-13
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT06830239 2026-02-12
Superhero
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT07381777 2026-02-02
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT07269249 2025-12-08
RW-NEDOS
National Cancer Institute, Naples
Recruiting
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT04926324 2025-06-29
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
Phase 1/2 Terminated
NCT05239546 2025-05-25
NAIO
University of Iowa
Phase 2 Recruiting
NCT06757244 2025-03-18
DOVIPA
Hopital Foch
Phase 2 Recruiting
NCT06762405 2025-02-18
PREDIR-NEOREC
Centre Hospitalier Universitaire Dijon
Phase 3 Recruiting
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT06059495 2024-02-05
DEWI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn